Sonoma Pharmaceuticals Receives Two New United Ara

PETALUMA, Calif., April 12, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced it has received two new regulatory approvals from the United Arab Emirates Ministry of Health & Prevention.

The first approval, for Pediacyn® HydroGel (hypochlorous acid), is intended for treatment of atopic dermatitis and other dermatoses forming a protective barrier against physical, chemical and microbial invasion of the atopic dermatitis lesions under the supervision of a healthcare professional.

The second approval, for Epicyn® Scar Hydrogel (hypochlorous acid), also under the supervision of a healthcare professional, is intended for the management of scars by forming a protective barrier against physical, chemical and microbial invasion of the scar.

Both offerings, based upon Sonoma’s patented Microcyn® Technology hypochlorous acid, will be supplied by MicroSafe Group International to the UAE beginning in May 2017.

“The regulatory process in the United Arab Emirates is distinct throughout Southwest Asia for being very thorough and rigorous. Therefore, earning these two UAE approvals will certainly open the path to growth and help to streamline regulatory approvals from many other countries in the region,” said Safwan Abdallah, MicroSafe group’s director of operations.  “The first of these two UAE approvals is for Pediacyn® HydroGel, an essential non-steroidal treatment for all types of dermatitis and dermatoses, which are common afflictions in our region due to severely humid conditions. The second approval for Epicyn® Scar Hydrogel is equally important. Epicyn® is intended to reduce the presence of old and new hypertrophic and keloid scars, resulting from burns, general surgical procedures and trauma wounds. Epicyn® can be used immediately upon appearance of a wound or straight after suturing of the wound. Access to these cutting edge advancements in dermatology will satisfy a significant unmet need for physicians across the UAE and increase the quality of life of patients’ suffering from these dermatological ailments.”

About Atopic Dermatitis In a 2015 study published in the Annals of Nutrition & Metabolism, atopic dermatitis is shown to be a chronic inflammatory skin disease posing a significant burden on health-care resources and patients' quality of life. A complex disease with a wide spectrum of clinical presentations and combinations of symptoms, atopic dermatitis affects up to 20% of children and up to 3% of adults; recent data show that its prevalence is still increasing, especially in low-income countries.

Scar Treatment Market According to a P&S Market Research report, the global scar treatment market accounted for $15,944 billion in revenue in 2015, and it is expected to grow at a CAGR of 10.0% during 2016-2022. The topical treatment segment dominated the global market in 2015 with about 60.9% share. The global scar treatment market is witnessing high growth rate, due to growing cases with skin problems leading to scar formation, availability of technologically advanced products, which have the capability to fade away the scars and increasing appearance consciousness among consumers. Also, the increasing expenditure on personal care is further propelling the growth of the market.

About Sonoma Pharmaceuticals, Inc. Sonoma is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com

Forward-Looking Statements Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “Company”). These forward-looking statements are identified by the use of words such as “believe,” “achieve,” and “strive,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its annual report on Form 10-K for the fiscal year ended March 31, 2017. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals®, Pediacyn®, Epicyn® and Microcyn® are registered trademarks of Sonoma Pharmaceuticals, Inc.  All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact: Sonoma Pharmaceuticals, Inc. Dan McFadden VP of Public and Investor Relations (425) 753-2105 dmcfadden@sonomapharma.com